May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Improvement of Visual Acuity and Resolution of Macular Edema Associated With Chronic Disciform Scars After Intravitreal Bevacizumab
Author Affiliations & Notes
  • S. N. Syed
    Ophthalmology, Univ of FL-Jacksonville, Jacksonville, Florida
  • S. Gupta
    Ophthalmology, Univ of FL-Jacksonville, Jacksonville, Florida
  • V. S. Brar
    Ophthalmology, Univ of FL-Jacksonville, Jacksonville, Florida
  • S. Grover
    Ophthalmology, Univ of FL-Jacksonville, Jacksonville, Florida
  • K. V. Chalam
    Ophthalmology, Univ of FL-Jacksonville, Jacksonville, Florida
  • Footnotes
    Commercial Relationships  S.N. Syed, None; S. Gupta, None; V.S. Brar, None; S. Grover, None; K.V. Chalam, None.
  • Footnotes
    Support  Foundation Fighting Blindness, Inc. Owing Mills, MD.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5586. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. N. Syed, S. Gupta, V. S. Brar, S. Grover, K. V. Chalam; Improvement of Visual Acuity and Resolution of Macular Edema Associated With Chronic Disciform Scars After Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5586. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate if intravitreal bevacizumab will improve retinal edema or subretinal fluid associated with chronic disciform scars secondary to macular degeneration

Methods: : This is a retrospective case series of 10 eyes of 10 patients ages 65 to 84 years with disciform scars and overlying retinal edema or subretinal fluid documented on OCT. All patients were treated with 2 or more injections of intravitreal bevacizumab at monthy intervals and were followed with OCT and IVFA to evaluate response to injections.

Results: : All patients had 20/200 or worse visual acuity as measured with snellen visual acuity testing, prior to injections with no significant improvement in visual acuity on follow up ranging from 4 to 12 months. Average central macular thickness measurements on OCT decreased from 409.7 µm to 278.2 µm, with an average decrease of 131.5 µm. OCT demonstrated cystic retinal edema in all patients and additionally showed subretinal fluid in 1 patient. On follow up retinal edema resolved completely in 6 patients (p<0.01).

Conclusions: : Though disciform scar represents the end stage of choroidal neovascularization, there does appear to be benefit in terms of anatomic improvement of retinal edema with active treatment. This suggests that VEGF is still actively involved at this stage of the disease process and actively responds to intravitreal therapy. Evaluation with visual functional questionnaire and low vision instrumentation pre and post injections may further delineate the advantages of reduction in retinal thickness with intravitreal bevacizumab.

Keywords: age-related macular degeneration • choroid: neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×